SARS-CoV-2 antibody immunoassays in serial samples reveal earlier seroconversion in acutely ill COVID-19 patients developing ARDS.
Marie-Luise BuchholtzFlorian M ArendPeter EichhornMichael WeigandAlisa KleinhempelKurt HäuslerMathias BruegelLesca M HoldtDaniel TeupserPublished in: PloS one (2021)
Serial sampling in COVID-19 patients revealed earlier seroconversion and higher signal ratios of SARS-CoV-2 antibodies as a potential risk marker for the development of ARDS, suggesting a utility for antibody testing in acutely diseased patients.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- end stage renal disease
- acute respiratory distress syndrome
- ejection fraction
- extracorporeal membrane oxygenation
- newly diagnosed
- mechanical ventilation
- chronic kidney disease
- single cell
- peritoneal dialysis
- prognostic factors
- genome wide
- risk assessment
- dna methylation
- patient reported outcomes
- climate change
- human health